Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Role of molecular diagnostics in prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.10.19
Views: 2643

Dr Elena Castro and Dr Shahneen Sandhu

Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Dr Shahneen Sandhu (Peter MacCallum Cancer, Melbourne, Australia) discuss the role of molecular testing in prostate cancer at ESMO 2019

Dr Sandhu discusses the personalised treatment of prostate cancer, including the use of molecular testing using archival tissue in the PROfound study.

The experts question how molecular testing can be implemented into clinical practice and describe this as a technical challenge.

The experts conclude by discussing the Australian and ESMO guidelines surrounding the use of molecular screening for prostate cancer patients.

This programme has been supported by an unrestricted educational grant from AstraZeneca.

Results from the PROfound trial
Novel imaging techniques
Precision medicine in prostate cancer: Tissue or plasma testing?
Clinical guidelines for prostate cancer
Updates in the ESMO guidelines


Related videos


no rating
Epidemiology of cancer in India

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation